Precision Therapeutics, Inc. Presents Clinical Data Demonstrating Prediction for Platinum Resistance to First-Line Chemotherapy in Primary Ovarian Cancer at WAGO
5/9/2013 10:50:04 AM
More...
|
Precision Therapeutics, Inc. Presents Clinical Data Demonstrating Prediction for Platinum Resistance to First-Line Chemotherapy in Primary Ovarian Cancer at WAGO
5/9/2013 8:16:33 AM
More...
|
Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian to be Presented by Precision Therapeutics, Inc. at WAGO Annual Meeting
5/6/2013 10:10:18 AM
More...
|
Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian to be Presented by Precision Therapeutics, Inc. at WAGO Annual Meeting
5/6/2013 7:11:39 AM
More...
|
Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian to Be Presented by Precision Therapeutics, Inc. at WAGO Annual Meeting
5/6/2013 6:45:05 AM
More...
|
Precision Therapeutics, Inc. Announces Topline Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian Cancer Using Personalized Chemotherapy Diagnostic ChemoFx®
3/11/2013 11:22:20 AM
More...
|
New Precision Therapeutics, Inc. Study Supports Potential Utility of ChemoFx in Primary Ovarian Cancer
11/12/2012 9:36:18 AM
More...
|
Precision Therapeutics, Inc. Release: New Study Shows Association Between ChemoFx® Results and Recurrence Free Survival
11/2/2012 8:27:30 AM
More...
|
Rosetta Genomics Ltd. (ROSG) and Precision Therapeutics, Inc. Announce U.S. Commercial Launch of miRview® Mets2
10/2/2012 10:53:27 AM
More...
|
Precision Therapeutics, Inc.' ChemoFx® Test Useful in Determining Treatment for Resistant and Recurrent Gynecologic Cancer Patients
9/6/2012 10:01:42 AM
More...
|
|